As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal ...
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) reported third-quarter financial results and detailed a rapidly accelerating push ...
DOHA: The View Hospital, in affiliation with Cedars-Sinai, offers Repetitive Transcranial Magnetic Stimulation (rTMS) therapy at its Psychiatry Department. This advanced, non-invasive treatment ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) in Yokohama, Japan, the Company's first cyclotron facility in ...
The FDA has granted 510(k) clearance and a label expansion for a transcranial magnetic stimulation device to treat patients ...
Q3 2025 Earnings Call Transcript November 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...
NRx has refiled its Abbreviated New Drug Application for KETAFREE™ (preservative free ketamine), received supportive correspondence from FDA, and expects Q2 2026 GDUFA date.HOPE Therapeutics is now ...
Moment of Clarity has published a new educational resource titled “How Deep TMS Therapy Works,” providing a comprehensive overview of transcranial magnetic stimulation (TMS) and its emerging role in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback